Cystic Fibrosis Clinical Trial
Official title:
A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients
Verified date | December 2022 |
Source | Savara Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).
Status | Completed |
Enrollment | 188 |
Est. completion date | January 15, 2021 |
Est. primary completion date | July 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility | Inclusion criteria 1. Participants =6 years of age at time of informed consent form or assent form signing. 2. Confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following: 1. Positive sweat chloride test (value =60 milliequivalent/L), 2. Genotype with 2 mutations consistent with CF (i.e., a mutation in each of the cystic fibrosis transmembrane conductance regulator genes). 3. Positive sputum culture or a throat swab culture for MRSA at Screening. 4. In addition to the Screening sample, have at least 2 prior sputum or throat swab cultures positive for MRSA, of which at least 1 sample is >6 months prior to Screening. At least 50% of all MRSA cultures (sputum or throat swab culture) collected from the time of the first positive culture (in the previous 1 year) must have tested positive for MRSA. (Note: Screening sample may count towards 50% positive count) 5. FEV1 =30% and =90% of predicted that is normal for age, gender, race, and height, using the Global Lung Function Initiative equation. 6. At least 1 episode of acute pulmonary infection treated with non-maintenance antibiotics within 12 months prior to the Baseline visit (initiation of treatment with intermittent inhaled anti-Pseudomonal therapy will not qualify as treatment with non-maintenance antibiotics). 7. If female of childbearing potential, an acceptable method of contraception must be used during the study and must be combined with a negative pregnancy test obtained during Screening; sexually active male subjects of reproductive potential who are non-sterile (i.e., male who has not been sterilized by vasectomy for at least 6 months, and were not diagnosed with infertility through demonstration of azoospermia in a semen sample and/or absence of vas deferens through ultrasound) must be willing to use a barrier method of contraception, or their female partner must use an acceptable method of contraception, during the study. For purposes of this study, the Sponsor defines "acceptable methods of contraception" as: 1. Oral birth control pills administered for at least 1 monthly cycle prior to administration of the study drug. 2. A synthetic progestin implanted rod (eg, Implanon®) for at least 1 monthly cycle prior to the study drug administration but not beyond the 4th successive year following insertion. 3. Intrauterine devices, inserted by a qualified clinician for at least 1 monthly cycle prior to study drug administration. 4. Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion. 5. Hysterectomy or surgical sterilization. 6. Abstinence. 7. Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam). Note: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal contraceptive exposure, reducing the effectiveness and increasing the incidence of menstruation-associated adverse reactions. Hormonal contraceptives, including oral, injectable, transdermal, and implantable, should not be relied upon as an effective method of contraception when co-administered with Orkambi. 8. Able and willing to comply with the protocol, including availability for all scheduled study visits and able to perform all techniques necessary to use the AeroVanc inhaler and measure lung function. 9. Agree not to smoke during any part of the clinical trial (Screening visit through end of study). 10. Participants with a Pseudomonas aeruginosa co-infection must either be stable on a regular suppression regimen of inhaled antibiotics or must be, in the opinion of the Investigator, stable despite the lack of such treatment. Exclusion criteria 1. Use of anti-MRSA treatments prescribed as maintenance therapy (intravenous [IV] or inhaled treatment within 28 days; oral treatment within 14 days) prior to the Baseline visit. 2. Use of non-maintenance antibiotic for pulmonary infection or extrapulmonary MRSA infection (IV or inhaled antibiotic within 28 days; oral antibiotic within 14 days) prior to the Baseline visit. 3. History of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or placebo except for a history of red-man syndrome. 4. Inability to tolerate inhaled products. 5. First time sputum culture or throat swab culture yielding Burkholderia cepacia, or nontuberculous Mycobacteria in the previous 6 months to Screening. 6. History of lung or other solid organ transplantation or currently on the list to receive lung or other solid organ transplantation. 7. Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus, or vancomycin intermediate resistant Staphylococcus aureus, with minimum inhibitory concentration =8 µg/mL). 8. Oral corticosteroids in doses exceeding 10 mg prednisone per day or 20 mg prednisone every other day, or equipotent doses of other corticosteroids. 9. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 14 days, or changes in cystic fibrosis transmembrane conductance modulators within 28 days, prior to the Baseline visit. 10. Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the subject or the quality of the study data. 11. Inability to tolerate inhalation of a short acting beta2 agonist 12. Oxygen saturation <90% at Screening. 13. Changes in physiotherapy technique or physiotherapy scheduled within 1 week of the Baseline visit. 14. Administration of any investigational drug or device within 4 weeks prior to the Screening visit and during the study 15. Female with positive pregnancy test result during Screening, pregnant (or intends to become pregnant), lactating or intends to breastfeed during the study. 16. Renal insufficiency, defined as creatinine clearance <50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation for children at the Screening visit. 17. Abnormal liver function, defined as =4x upper limit of normal of serum aspartate aminotransferase or serum alanine aminotransferase, or known cirrhosis at Screening. 18. Diagnosed with clinically significant hearing loss. 19. History of positive result for human immunodeficiency virus, hepatitis B virus or hepatitis C virus. 20. Planned hospitalizations for prophylaxis antibiotic treatment within 28 days prior to Baseline visit or during the double-blind period (Period 1). |
Country | Name | City | State |
---|---|---|---|
Canada | The Hospital for Sick Children | Toronto | Ontario |
Canada | British Columbia Children's Hospital | Vancouver | British Columbia |
United States | Albany Medical College | Albany | New York |
United States | University of New Mexico Pediatric/Pulmonary | Albuquerque | New Mexico |
United States | University of Michigan Health System | Ann Arbor | Michigan |
United States | Children's Health Care of Atlanta at Scottish Rite | Atlanta | Georgia |
United States | Augusta Univ Cystic Fibrosis Center | Augusta | Georgia |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | Austin Children's Chest Associates | Austin | Texas |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Medical University of South Carolina (MUSC) | Charleston | South Carolina |
United States | Levine Children's Hospital - Atrium Health | Charlotte | North Carolina |
United States | University of Virginia Health System, Cystic Fibrosis Center | Charlottesville | Virginia |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | University Hospital Cleveland Medical Center | Cleveland | Ohio |
United States | University Vermont Medical Center Vermont Lung Center | Colchester | Vermont |
United States | The Research Institute at Nationwide Children's Hospital | Columbus | Ohio |
United States | Children's Medical Center Cystic Fibrosis Clinic | Dallas | Texas |
United States | Dayton Children's Hospital | Dayton | Ohio |
United States | National Jewish Health Adult Cystic Fibrosis Center | Denver | Colorado |
United States | Wayne State University (HUH) | Detroit | Michigan |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Cook Children Medical Center | Fort Worth | Texas |
United States | University of Florida Pediatrics | Gainesville | Florida |
United States | Chicago CF Care Specialists | Glenview | Illinois |
United States | Penn State Children's Hospital | Hershey | Pennsylvania |
United States | Memorial Healthcare System | Hollywood | Florida |
United States | Texas Children's Hospital | Houston | Texas |
United States | Riley Hospital for Children at Indiana University Health | Indianapolis | Indiana |
United States | University of Iowa Department of Pediatrics | Iowa City | Iowa |
United States | Nemours Childrens Specialty Care | Jacksonville | Florida |
United States | Children's Mercy | Kansas City | Missouri |
United States | University of Kansas | Kansas City | Kansas |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Miller Childrens Hospital MemorialCare Health System Pediatric Pulmonology | Long Beach | California |
United States | Children's Hospital Los Angeles | Los Angeles | California |
United States | University of Southern California Keck Medical Center of USC | Los Angeles | California |
United States | University of Louisville Kosair Charities Pediatric Clinical Research Unit | Louisville | Kentucky |
United States | UTHSC Lebonheur Children's Hospital | Memphis | Tennessee |
United States | University of Miami Bachelor Children's Hospital | Miami | Florida |
United States | Pulmonary Associates of Mobile | Mobile | Alabama |
United States | West Virginia University | Morgantown | West Virginia |
United States | Morristown Medical Center | Morristown | New Jersey |
United States | NorthSurburban Pulmonary Specialists | Morton Grove | Illinois |
United States | Rutgers-Robert Wood Johnson Medical School | New Brunswick | New Jersey |
United States | Northwell Health, Div of Pulmonary, Critical Care & Sleep Medicine | New Hyde Park | New York |
United States | Columbia University Medical Center | New York | New York |
United States | University of Oklahoma Health Science Center - Pediatric Pulmonary & CF Center | Oklahoma City | Oklahoma |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Arnold Palmer Hospital Pulmonary and Sleep Medical Institute Orlando Health, Inc | Orlando | Florida |
United States | Central Florida Pulmonary Group | Orlando | Florida |
United States | Nemours Children's Hospital | Orlando | Florida |
United States | Nemours Children's Specialty Care | Pensacola | Florida |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | Children's Hospital of Pittsburgh of UPMCU | Pittsburgh | Pennsylvania |
United States | Maine Medical Partners Pediatric Specialty Care | Portland | Maine |
United States | Oregon Health and Science University | Portland | Oregon |
United States | UC Davis Medical Center | Sacramento | California |
United States | Cardinal Glennon Children's Hospital /Saint Louis University | Saint Louis | Missouri |
United States | Washington University | Saint Louis | Missouri |
United States | Johns Hopkins All Children's Hospital | Saint Petersburg | Florida |
United States | University of Utah Health Sciences Center | Salt Lake City | Utah |
United States | Seattle Children's Hospital | Seattle | Washington |
United States | Sanford Childrens Specialty Clinic | Sioux Falls | South Dakota |
United States | Providence Medical Research Center | Spokane | Washington |
United States | Toledo Children's Hospital CF Center | Toledo | Ohio |
United States | The University of Texas Health Science Center at Tyler | Tyler | Texas |
United States | Children's National Medical Center | Washington | District of Columbia |
United States | Via Christi Health Systems CF Clinic | Wichita | Kansas |
United States | Wake Forest School of Medicine | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Savara Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted | The mean absolute change from baseline in FEV1 percent predicted was analyzed sequentially at Week 4 (end of Cycle 1), Week 12 (end of Cycle 2) and at Week 20 (end of Cycle 3). | Baseline and Week 4, 12 and 20 | |
Secondary | Frequency of Pulmonary Exacerbations | The number of pulmonary exacerbations during Period 1 adjusted for the length of follow-up. | Week 20 | |
Secondary | Time to First Pulmonary Exacerbation | Time to first pulmonary exacerbation requiring use of another antibiotic medication (oral, IV, and/or inhaled). The Outcome Measure Data presented are the median percentiles and 95% confidence intervals from Kaplan-Meier estimates. | Week 20 | |
Secondary | Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Scores | The CFQ-R was administered every two weeks using a hand-held e-Diary. CFQ-R scores range between 0 and 100, where higher scores indicate a better outcome. The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning and Social Functioning. The Outcome Measure Data presented are the Respiratory Symptoms Scores. | Baseline and Week 4, 12, and 20 | |
Secondary | Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Symptom Score (CFRSD-CRISS) Scores | The CFRSD-CRISS was administered every two weeks using a hand-held e-Diary. Scores range between 0 and 100, where higher scores indicate a worse outcome. | Baseline and Week 4, 12 and 20 | |
Secondary | Relative Change in FEV1 Percent Predicted | The mean relative change from Baseline in FEV1 percent predicted | Baseline and Week 4, 12 and 20 | |
Secondary | Number of Successful Response Cycles | The number of successful response cycles a participant achieves over Period 1. A response in a cycle is defined by at least a 5 % relative improvement in FEV1 percent predicted at the end of each the respective cycle. | Week 20 | |
Secondary | Area Under the FEV1-time Profile | The mean treatment difference in FEV1 across all post-baseline visits | Week 20 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |